These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1361349)

  • 41. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen.
    Maino VC; Suni MA; Wormsley SB; Carlo DJ; Wallace MR; Moss RB
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):539-47. PubMed ID: 10777144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.
    Jones T
    Curr Opin Investig Drugs; 2010 Aug; 11(8):964-70. PubMed ID: 20721838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment.
    Bratt G; Eriksson LE; Sandström E; Gilljam G; Hinkula J; Albert J; Redfield R; Wahren B
    Int J STD AIDS; 1999 Aug; 10(8):514-21. PubMed ID: 10471100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Positive Phase 1 interim results for killed whole-virus HIV vaccine.
    Riedmann EM
    Hum Vaccin Immunother; 2013 Jan; 9(1):7. PubMed ID: 23442582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of delayed-type hypersensitivity with proteins made insoluble by polymerization.
    Kostiala AA; Jokinen EJ
    Cell Immunol; 1978 Jun; 38(1):1-13. PubMed ID: 667952
    [No Abstract]   [Full Text] [Related]  

  • 46. Commentary.
    Nolte FS
    Clin Chem; 2010 Oct; 56(10):1526. PubMed ID: 20876779
    [No Abstract]   [Full Text] [Related]  

  • 47. Interpretation of HIV serologic testing results.
    Mahajan VS; Pace CA; Jarolim P
    Clin Chem; 2010 Oct; 56(10):1523-6. PubMed ID: 20876778
    [No Abstract]   [Full Text] [Related]  

  • 48. Sample size estimation using repeated measurements on biomarkers as outcomes.
    Kirby AJ; Galai N; Muñoz A
    Control Clin Trials; 1994 Jun; 15(3):165-72. PubMed ID: 7913674
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The bactericidal capacity of peripheral blood monocytes from HIV positive patients may collapse very soon after the infection.
    Bravo-Cuellar A; Nowacki W; Vuillier F; de Saint-Martin J; Orbach-Arbouys S
    Immunol Lett; 1992 Feb; 31(3):297-9. PubMed ID: 1347755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time for a systematic look at inactivated HIV vaccines.
    Sheppard HW; Dorman BP
    AIDS; 2015 Jan; 29(1):125-7. PubMed ID: 25562497
    [No Abstract]   [Full Text] [Related]  

  • 51. Prolonged asymptomatic states in HIV-seropositive persons with 50 CD4+ T-cells/mm3: preliminary psychoimmunologic findings.
    Solomon GF; Benton D; Harker JO; Bonavida B; Fletcher MA
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1172-3. PubMed ID: 8105075
    [No Abstract]   [Full Text] [Related]  

  • 52. Cell-mediated immunologic memory in prevention and treatment of HIV disease.
    Salk PL; Salk J
    Res Immunol; 1994; 145(8-9):629-33; discussion 634-5. PubMed ID: 7754212
    [No Abstract]   [Full Text] [Related]  

  • 53. HIV inactivation: time for a second look.
    Rios A; Poteet EC; Siwak EB; Anderson DW; Yao QC
    AIDS; 2015 Jan; 29(1):129-31. PubMed ID: 25562498
    [No Abstract]   [Full Text] [Related]  

  • 54. Ontogeny of delayed hypersensitivity in young turkeys.
    McCorkle FM; Luginbuhl GH; Simmons DG; Morgan GW; Thaxton JP
    Dev Comp Immunol; 1983; 7(3):517-24. PubMed ID: 6642045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cellular immunologic parameters in HIV-positive patients with AIDS-related complex and intravenous immunoglobulin therapy.
    Krueger GR; Ramon A; Degenhardt S; Schrappe-Bächer M; Rasokat H; Koch B; Deninger J
    Vox Sang; 1990; 59 Suppl 1():30-7. PubMed ID: 2238574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Results of an open study for evaluating the effectiveness and tolerance of adjuvant administration of the ISF nutrient program in HIV positive patients].
    Fuchs N; Markolin G; Kuklinski B; Jäger R; Zelch N; Gurh I; Schicka G; Neumann K
    Wien Med Wochenschr; 1996; 146(18):483-93. PubMed ID: 9036684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune mechanisms in HIV-related neuropathies.
    Chavanet ; Giroud M; Solary E; Waldner A; Porter H
    Lancet; 1989 Sep; 2(8666):812-3. PubMed ID: 2571058
    [No Abstract]   [Full Text] [Related]  

  • 58. Preventive care for HIV-positive adults.
    Olson PE; Wallace MR; Weiss PJ; Kennedy CA
    JAMA; 1993 Aug; 270(5):577. PubMed ID: 8101233
    [No Abstract]   [Full Text] [Related]  

  • 59. Kenyan sex workers key to AIDS vaccine?
    Square D
    CMAJ; 2003 Apr; 168(9):1168. PubMed ID: 12719329
    [No Abstract]   [Full Text] [Related]  

  • 60. beta-Carotene in HIV infection.
    Coodley GO; Nelson HD; Loveless MO; Folk C
    Ann N Y Acad Sci; 1993 Dec; 691():277-8. PubMed ID: 8129311
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.